JTCS Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Benjamin B. Peeler
John A. Kern
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adams, J. D.
Right arrow Articles by Dake, M. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Adams, J. D.
Right arrow Articles by Dake, M. D.
Related Collections
Right arrow Great vessels
Right arrow Minimally invasive surgery

J Thorac Cardiovasc Surg 2009;137:117-123
© 2009 The American Association for Thoracic Surgery

Acquired Cardiovascular Disease

Endovascular repair of the thoracic aorta in the post-FDA approval era

Joshua D. Adams, MDa,b,*, John F. Angle, MDa, Alan H. Matsumoto, MDa, Benjamin B. Peeler, MDb, Bulent Arslan, MDa, Kenneth J. Cherry, MDb, John A. Kern, MDb, Michael D. Dake, MDa

a Department of Radiology, University of Virginia Health System, Charlottesville, Va
b Department of Surgery, University of Virginia Health System, Charlottesville, Va

Received for publication May 5, 2008; revisions received July 23, 2008; accepted for publication August 2, 2008.

* Address for reprints: Joshua D. Adams, MD, Department of Radiology, University of Virginia Health System, PO Box 800170, 1215 Lee St, Charlottesville, VA 22908. (Email: jda2d{at}virginia.edu).

Objective: Endovascular repair of thoracic aortic disease is rapidly progressing as an alternative to open surgical therapy. In March of 2005, the Gore TAG thoracic endoprosthesis (W. L. Gore & Associates, Inc, Flagstaff, Ariz) received Food and Drug Administration (FDA) approval for the treatment of descending thoracic aortic aneurysms. Subsequently, off-label use of the technology expanded to include additional thoracic aortic diseases. The purpose of this study was to examine whether the outcomes with this device changed after the inclusion and exclusion criteria of FDA-controlled trials no longer governed patient selection.

Methods: A retrospective analysis was performed on all patients who underwent endovascular repair of the thoracic aorta with the Gore TAG device at our institution between March 23, 2005, and September 8, 2006.

Results: Fifty consecutive patients with a broad range of aortic pathologic conditions were included in the study. The results in this group compared with those of the phase II trial included the following: length of stay, 7.5 versus 7.6 days (P = .97); intensive care unit stay, 3.7 versus 2.6 days (P = .61); 30-day mortality, 2.0% versus 1.5% (P = .68); spinal cord injury, 2% versus 3% (P = .89); stroke, 4% versus 4% (P = .67); early endoleaks, 26% versus 4% (P < .01); and late endoleaks, 18% versus 7% (P = .08). At 1 year, overall survival was 92% compared with 82% in the phase II trial.

Conclusions: In the post-FDA approval era, endovascular stent-graft therapy is frequently applied to patients with more challenging thoracic aortic anatomy and a wide range of pathologic conditions. Our results in this group are similar to outcomes reported for patients with descending thoracic aortic aneurysm exclusively.

Abbreviations and Acronyms CSF = cerebral spinal fluid; CT = computed tomography; FDA = Food and Drug Administration; ICU = intensive care unit






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.